Key result
Interleukin-6 contributed to the progression of heart failure via the AT1-R pathway, and treatment with losartan attenuated the decrease in nNOS and increases in IL-6, CRH, and NE.
Why the study?
Does paraventricular nucleus infusion of losartan and/or IL-6 alter heart failure progression and sympathetic activity in a rat model of HF?
Does paraventricular nucleus infusion of losartan and/or IL-6 alter heart failure progression and sympathetic activity in a rat model of HF?
Interleukin-6 contributes to the progression of heart failure and sympathoexcitation via the AT1-R pathway in the paraventricular nucleus, which can be attenuated by losartan.
Answers are grounded in this paper and cite their sources.
Central IL-6/AT1-R signaling may drive rat HF progression; leaves open translation to human therapy.
The association between interleukin‑6 (IL‑6) and angiotensin II receptor 1 (AT1‑R) in modulating the progression of heart failure (HF) remains to be fully elucidated. The aim of the present study was to investigate the mechanism of IL‑6 and AT1‑R in a model of HF induced by surgery. Male Sprague‑Dawley rats were randomly divided into five groups, including sham surgery and vehicle groups. The animals were treated for 4 weeks via paraventricular nucleus infusion with either vehicle, losartan (LOS; 200 µg/day), IL‑6 (1 µg/day) or LOS and IL‑6 together (LOS+IL‑6). The rats with HF had higher levels of IL‑6, corticotropin‑releasing hormone (CRH) and norepinephrine (NE), and a lower level of neuronal nitric oxide synthase (nNOS), compared with the rats in the sham surgery group. Treatment with LOS attenuated the decrease in nNOS and the increases in IL‑6, CRH and NE; whereas treatment with IL‑6 facilitated the lower expression of nNOS and higher expression levels of IL‑6, CRH and NE. No differences in the expression levels of nNOS, CRH or NE were found between the LOS group and LOS+IL‑6 group. The results of the study demonstrated that IL‑6 contributed to the progression of HF via the AT1‑R pathway.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2017) studied Heart failure (n=50). Losartan and Interleukin-6 vs. Vehicle and Sham was evaluated on Left ventricular function and sympathetic activity markers (nNOS, CRH, NE). Interleukin-6 contributed to the progression of heart failure via the AT1-R pathway, and treatment with losartan attenuated the decrease in nNOS and increases in IL-6, CRH, and NE.
Synapse has enriched 10 related papers. Consider them for comparative context: